Head to Head Survey: BioCryst Pharmaceuticals (BCRX) and Its Competitors

BioCryst Pharmaceuticals (NASDAQ: BCRX) is one of 287 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare BioCryst Pharmaceuticals to similar companies based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.

Profitability

This table compares BioCryst Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioCryst Pharmaceuticals -167.58% -123.16% -38.71%
BioCryst Pharmaceuticals Competitors -5,441.68% -162.70% -35.92%

Earnings and Valuation

This table compares BioCryst Pharmaceuticals and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioCryst Pharmaceuticals $26.35 million -$55.14 million -8.77
BioCryst Pharmaceuticals Competitors $290.27 million $35.99 million 54.45

BioCryst Pharmaceuticals’ peers have higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent recommendations and price targets for BioCryst Pharmaceuticals and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCryst Pharmaceuticals 0 3 7 0 2.70
BioCryst Pharmaceuticals Competitors 925 3348 11862 238 2.70

BioCryst Pharmaceuticals presently has a consensus target price of $9.14, suggesting a potential upside of 62.97%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.55%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe BioCryst Pharmaceuticals is more favorable than its peers.

Risk and Volatility

BioCryst Pharmaceuticals has a beta of 3.05, indicating that its stock price is 205% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals’ peers have a beta of 2.41, indicating that their average stock price is 141% more volatile than the S&P 500.

Institutional & Insider Ownership

84.7% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.8% of BioCryst Pharmaceuticals shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

BioCryst Pharmaceuticals peers beat BioCryst Pharmaceuticals on 7 of the 13 factors compared.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.